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Background: People in prison have a higher burden of blood-borne virus (BBV) infection than the general
population, and prisons present an opportunity to test for BBVs in high-risk, underserved groups. Changes to
the BBV testing policies in English prisons have recently been piloted. This review will enable existing evidence to
inform policy revisions. We describe components of routine HIV, hepatitis B and C virus testing policies in prisons
and quantify testing acceptance, coverage, result notification and diagnosis.Methods:We searched five databases
for studies of both opt-in (testing offered to all and the individual chooses to have the test or not) and opt-out
(the individual is informed the test will be performed unless they actively refuse) prison BBV testing policies.
Results: Forty-four studies published between 1989 and 2013 met the inclusion criteria. Of these, 82% were
conducted in the USA, 91% included HIV testing and most tested at the time of incarceration. HIV testing
acceptance rates ranged from 22 to 98% and testing coverage from 3 to 90%. Mixed results were found for
equity in uptake. Six studies reported reasons for declining a test including recent testing and fear. Conclusions:
While the quality of evidence is mixed, this review suggests that reasonable rates of uptake can be achieved with
opt-in and, even better, with opt-out HIV testing policies. Little evidence was found relating to hepatitis testing.
Policies need to specify exclusion criteria and consider consent processes, type of test and timing of the testing
offer to balance acceptability, competence and availability of individuals.
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Introduction
The prison estate in England and Wales holds approximately84 000 people with almost 200 000 passing through the system
each year.1,2 People in prison tend to have both a higher burden of
disease and poorer access to healthcare.3 Infection with blood-borne
viruses (BBVs) is higher than the general population largely due to
higher levels of injecting drug use.4 At any given time in the UK
detention estate, there are approximately 40 000 problematic drug
users with 55% of new prisoners testing positive for Class A drugs.5
People who inject drugs (PWIDs) are also repeatedly incarcerated
with more than 40% having been in prison at least five times.5
Further, there is a risk of amplification of infectious disease in
prisons because of overcrowding, the high prevalence of BBVs, a
lack of knowledge among prison staff, limited facilities for
diagnosis and treatment, large turnover and high-risk activity such
as unprotected sex.6
In 2010, out of 6750 new HIV diagnoses in the UK, only 2.4%
(160) were infected through injecting drugs.2 Prevalence data are
limited but suggest a higher rate of HIV infection in the prison
population: 0.22% versus 0.14% in the UK as a whole.2 An
anonymous testing study in eight prisons across England and
Wales in 1997–98 reported a prevalence of 0.4%, based on 82%
uptake.7 The 2001 National Sexual Health and HIV Strategy high-
lighted that people in prisons have particular HIV prevention re-
quirements.8 More recently, Public Health England (PHE) has
focused on expanding HIV testing to reduce late diagnoses and rec-
ommends routine HIV testing for all general medical admissions in
areas of high prevalence (estimated prevalence of undiagnosed HIV
>= one per 1000 population aged 16-59 years).9
Sentinel surveillance in England for 2010 showed that a higher
proportion of people in prison tested positive for hepatitis C than in
all community health settings except for drug dependency services.3
In England in 1997/98, 7% of people in prison were positive for anti-
hepatitis C virus (HCV, 31% of PWIDs) and 8% were positive for
hepatitis B virus (HBV) core (20% of PWIDs).7 However, there have
been significant changes in the epidemiology of HBV infection
amongst PWIDs alongside changes in the UK HBV vaccination
policy. In 1989, the Prison Service introduced a policy to vaccinate
‘at risk’ inmates who were in prison for more than 6 months and was
soon extended to include all sentenced prisoners.10 In 1996, a super-
accelerated HBV immunization schedule started for all UK
prisoners,10,11 followed in 2003 by a hyper-accelerated HBV vaccin-
ation programme in England and Wales.12 In 2003, 37% of HBV
diagnoses were due to injection drug use compared to only 4% by
2011.12
The Chief Medical Officer’s 2012 Report and the Liver Disease
Atlas of Variation 2013 emphasized the burden of liver disease and
the role of infectious hepatitis, especially undiagnosed infection.12,13
There is variation in hepatitis C testing across prisons in England.
An audit of 20 prisons found that only 62% of prisons had a written
HCV policy of which 92% included criteria for testing but with
variation in how testing was offered.14 There was a 47% increase
in HCV testing in prisons in England between 2005 and 2008 and a
35% increase in HBV testing, but the proportion of prisoners tested
has remained low.11 The Prison Health Performance Quality
Indicators include criteria for HCV testing and the need for
testing data to be recorded and submitted.5 However, these data
show that in 2013, only 7.8% of new receptions to prison were
tested for HCV infection.15
Prisons are places that provide an opportunity to test for BBVs in
high-risk and underserved groups. Different models of testing policy
exist. Routine testing models include both opt-in (where testing is
offered to all and the individual chooses whether to have the test)
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and opt-out (where the individual is informed the test will be
performed unless they actively refuse) although this distinction is
not used consistently in the literature. Other models include testing
on referral or request; risk assessment based testing and ad hoc
processes. Considerations around routine testing models need to
include confidentiality, the potential for reinforcing stigma in the
wider community with systematic testing of this population and
ensuring that the rationale for testing is patient centred. Further,
opt-out models have been criticized for the potential for the test
to appear mandatory to the person in prison.16,17 However, the
potential advantages of routine testing are to diagnose infection
and so commence earlier treatment with better outcomes; to
inform those with infection and enable subsequent behaviour
change to reduce transmission; to encourage risk reduction
amongst those who have negative test results; to reduce testing-
related stigma and discrimination by normalizing the testing
process and to reduce inequity in testing and diagnosis. Although
there is undiagnosed infection in both community and prison
settings, there is evidence to suggest that in prisons a large
proportion of BBV infections are in people who do not report
recognized risk factors and therefore only testing those identified
as high risk will leave infections undiagnosed.18
In April 2013, NHS England assumed commissioning responsibil-
ity for the prison estate.19 A single national commissioner offers the
opportunity for quality, evidence-based, consistent services to be
implemented with continuity of care as individuals move around
the detention estate. PHE, The Hepatitis C Trust, British Liver
Trust and National AIDS Trust all now advocate opt-out BBV
testing in prisons.20 A recent National Partnership Agreement
between the National Offender Management Service and NHS
England, supported by PHE, has committed to implementing an
opt-out BBV testing policy in adult prisons and developing care
pathways for those found to be infected by April 2014.21
Rationale and objectives
Changes to the BBV testing policies in prisons in England have
recently been proposed and we were unable to identify a
systematic review of the literature to date to inform this policy
change. The objectives of this article are to review existing
literature concerning the impact of routine BBV testing in prisons,
to describe the components of routine BBV testing policies and to
quantify BBV testing acceptance, coverage, result notification and
diagnoses under such policies.
Methods
Search strategy and selection criteria
Our searches, based on PRISMA guidelines, were conducted in
autumn 2013.22 Five electronic databases were searched: Scopus,
Medline, Cochrane, Web of Science and Global Health plus hand
searching reference lists of key articles. Combination search terms
were guided by an initial scoping review and previous research and
included ‘offender*’, ‘prison*’, ‘jail*’, ‘correctional’, ‘detention’,
‘inmate*’, ‘blood borne virus’, ‘hiv’, ‘hbv’, ‘hcv’, ‘hepatitis’, ‘test*’,
‘screen*’.23 An example search term for Scopus database is (TITLE-
ABS-KEY(offender* OR prison* OR jail* OR correctional OR
detention OR inmate*) AND TITLE-ABS-KEY((blood borne
virus) OR hiv OR hbv OR hcv OR hepatitis) AND TITLE-ABS-
KEY(test* OR screen*)).
We included studies relevant to the question of the impact of
routine BBV testing in the prison setting, available in English with
no limits on date of publication or geographical location. We
included studies of general correctional facility populations but
excluded studies of subgroups (excluding gender). We included
studies that considered routine (opt-in and opt-out) testing of all
inmates but excluded mandatory policy studies. Owing to the ethical
and legal complexity of mandatory testing, viewed by many as a
breach of human rights, we decided that mandatory testing
policies were outside the scope of this review. We included review
articles with documented methodology; experimental studies; obser-
vational studies; studies reporting perspectives of BBV testing
(including qualitative methodologies); cost-effectiveness studies
and intervention description and evaluation.
Data extraction
Data extraction was informed by The Cochrane Handbook
guidelines.24 Extracted data included year of publication,
population and country of study, specific location, methodology,
BBV, testing policy and main results. Data extraction was also
specific to the type of study and based on other guidelines, e.g.
review articles were based on the PRISMA checklist22; qualitative
studies were based on the Supplementary Guidance for Inclusion
of Qualitative Research in Cochrane Systematic Reviews of
Interventions.25 Two reviewers (D.J.P. and C.R.) appraised the
studies and extracted the data of interest.
Risk of bias assessment
For experimental study designs, we considered potential for bias in
four main areas: random sequence generation; allocation conceal-
ment; blinding of outcome assessment and completeness of
outcome data, using the Cochrane risk of bias tool.26 For observa-
tional studies, three areas of potential bias were graded as low, unclear
or high: selection bias, information bias and confounding. Qualitative
studies were evaluated using the four domains suggested in the
Cochrane guidance: credibility, transferability, dependability and
confirmability.27 Non-comparative evaluation descriptions were not
assessed in terms of bias because there is no participant selection
process or measurement of two groups for comparison. However,
they offer valuable information for this review and so have been
included. We used the extracted data and assessment of potential
bias to inform our assessment of overall study quality.
Results
For article screening and selection process, see the PRISMA
flowchart (figure 1). In total, 1961 articles were screened by title
for inclusion. Three hundred and thirty-five full text articles were
assessed and 44 met the eligibility criteria (table 1).
Six reviews fulfilled the inclusion criteria of having a documented
methodology including high-quality systematic reviews, reviews and
selected bibliographies (table 2).44,47,50,51,58,60 Thirty-three papers
were mainly quantitative, two were qualitative and three were
cost-effectiveness studies. Of the non-review articles, 31/38 (82%)
were conducted in the USA [nine at the Rhode Island Department of
Corrections (RIDOC)], four in the UK,48,61,65,66 one in Australia70
and two in Jamaica.16,29 Of the 33 quantitative studies, three
were experimental34,53,54 and 15 observational: 13 cross-
sectional29,30,36–42,49,56,59,67; one longitudinal57 and one before–after
study.55 We classified 15 papers as ‘descriptive’ that present descrip-
tion of routinely collected data such as evaluation, audit, process
data and/or description of either single or multiple routine BBV
testing interventions.16,28,31–33,35,43,45,48,61–64,68,70 Two qualitative
studies are included from the same project46,52; two other papers
included a qualitative component.33,59
The majority of the studies focused on HIV infection with 40/44
(91%) including routine testing for HIV infection, 8/44 (18%)
including routine testing for HCV and 5/44 (11%) including
routine testing for HBV. One of these only included HBcAb as a
surrogate marker for a history of risk behaviour for HIV infection.30
Three papers included HBV, HCV and HIV routine testing.58,61,70
Twenty-seven studies reported on the gender of the inmates:
3 were female only41,45,53; 14 included both men and
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women30,31,35,37–39,42,43,55,57,63,67,68,70 and 11 were male
only.16,29,33,34,36,48,49,52,54,56,64 One study disaggregated by gender to
include transgender.68
Intervention components
Tables 3 and 4 present the testing policy components and outcomes
from 17 papers with sufficient detail reported, some with multiple
interventions. Two other US multisite interventions (reported in
three papers) had different interventions at each site and are
excluded from these tables as sufficient data could not be
disaggregated for each intervention.31,42,62 We classified 11 interven-
tions as having an opt-in model,16,30,36,39,41,48,49,55,61,64,70 and 8 with
an opt-out16,32,33,35,53,54,63,64 (two have both).
Exclusions from testing offer
Three studies explicitly reported excluding those without capacity to
consent.53,54,63 One study included those without capacity to
consent for opt-out testing ‘as they are at increased risk of sexual
abuse while incarcerated and therefore will benefit from such
testing’.16 Three studies excluded prisoners with a previous HIV
diagnosis.55,63,64 Other studies had varying exclusion criteria for
study participation including non-English speaking.
Two prospective studies of opt-out oral swab HIV testing in
Connecticut jails (one female, one male) compared testing rates at
three time points: immediate (Day 0), early (Day 1) and delayed
(Day 7) and present data on those without capacity to consent.53,54
In the immediate testing group, 10% (male jail) and 11% (female
jail) were deemed medically incompetent/lacking capacity to consent
compared to statistically significant lower proportions in the other
groups: early and delayed testing (males 0% and 0%, females 4% and
4%, respectively).54
Consent processes
Seven papers did not clearly describe consent processes,16,30,41,48,61,63,70
whilst a further four studies only stated that ‘informed consent’ was
required.35,36,39,55 One required verbal consent,64 two required written
consent33,49 and two required verbal consent for the test (to replicate
the situation outside of study conditions) but written consent to par-
ticipate in the study.53,54 One study included three sites with different
processes (one written, one verbal and one that required no separate
consent for the HIV test).32
Timing
All interventions reported the timing of the testing offer. Sixteen
tested on arrival (within 28 days), whilst one described a routine
testing offer to all, including both new (incarcerated <6 months) and
existing inmates.16 In the two Connecticut prospective, controlled
trials of opt-out testing, both male and female immediate testing
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Figure 1 PRISMA flowchart
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groups had more refusals (female: 32%; male: 50%) compared with
early testing (female: 7%; male: 20%) and delayed testing groups
(female: 12%; male: 16%).53,54 See above for the higher proportions
of those deemed medically incompetent in the immediate groups.
However, the early and delayed groups had higher proportions of
those not available for testing because they were bonded, been
released or at court. In the female jail, the early testing group was
significantly more likely to be tested than the immediate or delayed
groups. In the male jail, both the early and immediate testing groups
were significantly more likely to be swabbed with no significant
difference between the early and immediate groups.
Three of the lowest HIV opt-out testing rates were with testing on
arrival but delayed beyond the first 48 h.32,53,54 An evaluation of an
opt-out programme found that with testing delayed until Days 3–4
(compared to at medical intake at two other sites), there was a
greatly reduced HIV test offer rate of 3% compared with 100%
and 89%.32 The low uptake is attributed in part to the delay in
testing but there are likely many confounding factors limiting
conclusions.
Testing procedure
Venous blood sampling was used in 12 studies in at least one testing
site,16,30,32,35,39,41,48,49,55,61,64,70 two studies used dried blood spot
testing16,36 and five used oral testing.33,32,53,54,63 Three studies
reported false positives on initial HIV testing,36,53,54 whilst one
study reported a false-negative rapid HIV test33 and other studies
reported indeterminate test results.38 Seven studies used rapid
testing regimes compared with standard tests.16,32,33,36,53,54,63 Two
studies reported qualitative preferences for rapid testing over
standard testing: one considering the staff perspective33 and
another the views of RIDOC inmates in which 88% of respondents
preferred rapid testing.37
Testing acceptance
A review on the acceptability of voluntary HIV testing in the USA
found test acceptance rates of 47-89% in prisons.50 This was
based on four studies and highlighted that the characteristics of
programmes and inmates’ HIV risk profiles differed greatly
Table 1 Table of included studies
Author Study design HIV HBV HCV Setting Sample Quality
assessment
Amankwaa et al.28 Descriptive Y USA 51 jurisdictions Low
Andrinopoulos et al.16 X-sectional Y Jamaica 1560 male inmates High
Andrinopoulos et al.29 X-sectional Y Jamaica 298 male inmates Low
Andrus et al.30 X-sectional Y Y USA 995 male and female inmates High
Arriola et al.31 Descriptive Y USA 1020 male and female inmates Low
Beckwith et al.32 Descriptive Y USA 129084 inmates High
Beckwith et al.33 Descriptive Y USA 1364 inmates High
6 staff (interviews)
6 staff (focus group)
Beckwith et al.34 Prospective controlled trial Y USA 264 male inmates Low
Beckwith et al.35 Descriptive Y USA 140739 inmates High
Beckwith et al.36 X-sectional Y USA 100 male inmates High
Beckwith et al.37 X-sectional Y USA 154 male and female inmates High
Begier et al.38 X-sectional Y USA 6411 male and female inmates High
Behrendt et al.39 X-sectional Y USA 2842 inmates (serological data) High
100 inmates (survey)
Belenko et al.40 X-sectional Y USA 11 agencies High
37 facilities
Cotten-Oldenberg et al.41 X-sectional Y USA 680 female inmates High
de Voux et al.42 X-sectional Y USA 766 male and female inmates Low
Desai et al.43 Descriptive Y USA 3493 male and female inmates High
Enel et al.44 Review Y NA Not applicable (NA) Low
Farley et al.45 Descriptive Y USA 110 female inmates Low
Grinstead et al.46 Qualitative Y USA 72 in-prison service providers High
Hahne et al.47 Review Y Y European NA High
Horne et al.48 Descriptive Y UK 3034 male inmates High
Hoxie et al.49 X-sectional (repeated) Y USA 4307 male inmates High
Irwin et al.50 Review Y NA NA Unclear
Jurgens51 Review Y Y NA NA Low
Kacanek et al.52 Qualitative Y USA 105 male inmates High
Kavasery et al.53 Prospective controlled trial Y USA 323 female inmates High
Kavasery et al.54 Prospective controlled trial Y USA 298 male inmates High
Liddicoat et al.55 Before-after Y USA 1004 male and female inmates Low
MacGowan et al.56 X-sectional Y USA 547 male inmates Low
McCusker et al.57 Longitudinal Y USA 1408 male inmates Low
Niveau58 Review Y Y Y NA NA Low
Sabharwal et al.59 X-sectional Y USA 215 health care workers High
Seal60 Review Y NA NA Low
Skipper et al.61 Descriptive Y Y Y UK 1618 inmates High
Spaulding et al.62 Descriptive Y USA 877119 male and female inmates High
Spaulding et al.63 Descriptive Y USA 39073 male and female inmates Unclear
Strick et al.64 Descriptive Y USA 34278 male inmates High
Sutton et al.65 Cost effectiveness Y UK NA High
Sutton et al.66 Cost effectiveness Y UK NA High
Sykes and Piquero67 X-sectional Y USA 25167 male and female inmates Low
Tartaro and Levy68 Descriptive Y USA 698 male and female inmates Low
Varghese and Peterman69 Cost effectiveness Y USA NA Low
Watkins et al.70 Descriptive Y Y Y Australia 946 male and female inmates High
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between studies. Table 4 reports the percentage of inmates who
accepted the test as a proportion of those who were offered the
test. Overall, 14 studies had sufficient data to calculate acceptance
rates.16,30,32,33,36,39,41,48,49,53–55,61,63 Figure 2 presents HIV test
acceptance by testing policy and demonstrates that higher
acceptance rates were achieved with opt-out testing. In the studies
that report opt-out testing, acceptance rates ranged from 22 to
98%16,32,33,53,54,63 and for opt-in, the range was 40-
73%.16,30,39,41,49,55 One opt-in study (excluded from figure 2) had
an acceptance rate of 95%, but this included only 100 participants,
and the rate was calculated with the number of consenting partici-
pants as the baseline and therefore will overestimate the true
acceptance rate.36 For HCV, one opt-in study presented their
acceptance rate as 12.4%.48 Some studies present an acceptance
rate deduced from a selected prison population denominator, e.g.
Andrinopoulos et al.16 that only includes inmates who accept prior
counselling. These values will then give the maximum possible
acceptance rate, and the true rate for the total prison population
would be lower. Conversely, in two similar studies in Connecticut,
more inmates were swabbed than gave written consent to participate
in the study (144 men swabbed, 130 participated in study; 192
females swabbed, 151 consented to participate) and therefore
results will likely underestimate testing uptake.53,54
Six studies comment on common reasons for declining a test
which are having had a recent test36,39,53–55,68; not perceiving
themselves to be at risk36,39,53–55; fear of a positive result39; dislike
of venepuncture/fear of testing30,39,53,68; concern over confidential-
ity39; not being comfortable with the tester or the test environ-
ment36; already knowing themselves to be HIV infected36,53,54;
being too tired/sleeping/watching TV53,68; experiencing
withdrawal53 and not being interested.54 In addition, there were
perceived negative consequences of testing positive such as being
isolated. More positive reasons for having an HIV test included
curiosity and it being free of charge.52
Testing coverage
Under opt-out HIV testing the proportion of total inmates tested
ranged from 3 to 90%32,35,53,54,63,64 and for opt-in 25–
72%.30,39,41,49,55,64,70 For HCV, three studies (all opt-in) report
rates of 9%,61 12%48 and 35%.70 For HBV, there was only one
opt-in study where 30% of entrants were tested (table 4).70
There were challenges to calculating coverage rates. Different
exclusion criteria were used, and the population total was not
always reported. A key reason for not receiving a test is not being
offered one. A number of studies describe a policy in which all new
entrants are offered testing and make an assumption that 100%
actually receive the offer. Seven studies reported a 100% testing
offer in at least one testing site.30,32,39,41,48,49,61 However, other
studies highlighted that less than 100% actually received the offer
despite a policy to offer testing to all32,53–55,63 and the proportion of
those offered screening decreased as the time from admission to
testing increased.53,54
Equity in uptake
One concern is that those at highest risk may opt-out of testing, but
the studies in this review generally do not support this. Only one
study found that a high-risk group, those incarcerated for a drug
offense, were 25% more likely to refuse testing.39 In other studies,
those with known risk factors or those who perceived themselves to
be at higher risk were either significantly more likely to accept
testing or there was no significant difference between high- and
low-risk groups.30,41,49,50,53,54,56
Mixed results were found amongst other subgroups. Five studies
found no significant association between ethnicity and acceptance
of routine testing,30,41,49,54,56 whilst two studies did.39,67 Behrendt
et al.39 found that African-Americans were 20% more likely to
refuse testing. A prospective controlled study of opt-out HIV
testing found that being Hispanic was significantly associated with
being tested in a bivariate model but not in the multivariable
model.53 An analysis of two large national prisoner surveys found
significant racial differences in HIV testing with blacks more likely to
be tested for HIV at admission than whites by about 29%.67 Four
studies report no significant association between age and testing
acceptance.16,30,54,57 However, four other studies found that
younger age groups were more likely to accept an HIV
test.39,49,53,56 Two studies reported no significant association
between HIV testing rates and gender,30,39 whilst two other studies
Table 2 Summary of review articles
First author Relevant inclusion criteria No. papers relevant Authors conclusions (relevant to prisons)
Enel et al.44 Articles published 1983–89
French, English, Italian articles
Publications relating to AIDS and ethics, human
rights, confidentiality, legislation or jurisprudence
2 Opinion is widely varied about the ethics of HIV screening
Ethical considerations of screening in prisons include:
additional isolation of HIV-infected prisoners, increased
discrimination, informed consent for screening
Hahne et al.47 Articles published 2000-12
34 European countries
English language
Peer-reviewed literature
Studies reporting estimated costs per additional
chronic infection (HBV and HCV) identified and/or
costs per life year gained
HBV=0
HCV=2
Insufficient evidence identified relating to cost-effective-
ness of screening of prisoners for HBV and HCV to draw
conclusions
Irwin et al.50 Articles published 1985-95
Studies addressing rates or determinants of HIV
counselling and testing
4 HIV test acceptance rate in prisons: 47-89%
Characteristics of programmes and inmates’ HIV risk
profiles differed greatly between studies
Jurgens51 Grey and peer-reviewed literature
Articles selected as most relevant and recent
Not available Evidence that routine HIV testing can result in large
numbers of prisoners accepting HIV testing. Benefits of
testing are enhanced by pre and post test counselling
Niveau58 Articles published 1993-2003
Articles in English, French and Spanish
Grey and peer reviewed literature
Articles relating to infectious disease (including HIV,
HBV and HCV) in the prison setting
Not available Effective screening policies involve voluntary screening of
the greatest number of people in prison
Testing should be proposed as soon as possible after arrival
Screening should be systematic for HIV, HBV, HCV
Seal60 Articles published 2004-05 relating to HIV and cor-
rectional populations
Articles with English abstracts
43 No studies were identified that examined HIV testing
acceptability
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Routine testing for BBVs in prisons 7 of 11
found a significant association (in one males were more likely to be
tested and in the other females).67,70
Notification of results
Five studies included the proportion of inmates receiving HIV test
results,33,36,53,54,64 three of which used conventional (non-rapid)
testing and describe giving results to the majority of those
tested.53,54,64 In one of these, only data for those with positive
results were presented and one HIV positive result was notified
post release.64 A rapid HIV testing study reported that 100% of
participants received initial results during the testing session.36
However, the protocol for another rapid HIV testing study
specified that those testing negative were not routinely informed
of results but are given contact information if they wish to check
their result.33 Three studies present qualitative findings relating to
notification of results from both provider and inmate perspec-
tives.33,46,52 Common themes include that those with negative
results are often not informed and a general assumption of ‘no
news is good news’. Inmates may learn about a positive test by
being moved accommodation or called to an appointment with
the HIV specialist, whereas others described being called to the
medical facility with the assumption that this meant the result was
positive when in fact another issue was to be addressed.46,52
New infections diagnosed
All 17 interventions report the number of infections identified.
Table 4 presents the percentage of new cases identified through
routine testing as the proportion of new cases over the total
number of tests performed. A key limitation is that data about
previous diagnoses are not always available or accurate and
therefore may overestimate the number of new cases identified by
the programme. New case identification rates for HIV opt-out
programmes range from 053 to 3.5%,16 but all bar one are below
1%. For HIV opt-in schemes, rates range from 036 to 5.4%.39 These
rates should not be directly compared, as the time when the studies
were conducted will affect the HIV prevalence rate. In addition, the
numbers of HIV diagnoses were very small making meaningful stat-
istical analysis difficult. The numbers and percentages were much
higher for hepatitis: for HCV new cases identified as a proportion of
total tests were 12%,48 24.8%70 and 29.9%.61
Undiagnosed infection
Four studies offer information on the proportion of HIV infections
identified by opt-in testing programmes.30,38,39,49 All estimated the
total number of HIV infections through anonymous serosurvey and
compared them to those obtained through routine testing (with or
without self-reporting included). In one study, 47% of inmates
underwent routine testing but this failed to detect 56% of the HIV
cases identified through serosurvey.39 For the other three studies, the
results were 50% of cases undetected (65% tested)30; 28%
undetected (55% tested)49 and 24% undetected (unknown %
tested).38 All support the finding that a significant percentage of
HIV infection remains undiagnosed with opt-in HIV testing. We
found no studies that explored this quantitatively with opt-out
testing.
The studies considering undiagnosed infection have important
limitations. Those with previously diagnosed infection may not
disclose their status and may also decline testing and thus will
appear in the ‘undiagnosed’ group. Second, those with a history of
injection drug use are less likely to have remnant serum for
serosurvey testing which may bias the results relying on the use of
remnant serum. For example, 31% of those who had a medical
intake examination did not have an adequate remnant sample for
HIV serosurvey testing and were more likely to be black; older and a
PWID.38 Third, the numbers of HIV diagnoses are often small thus
limiting meaningful analysis, such as one study that identifies 12
HIV positive inmates of which six were identified by routine
testing.30
Discussion
This review demonstrates that a number of studies have investigated
the effectiveness and impact of routine BBV testing policies in
prisons. Overall, the evidence suggests that reasonable rates of test
uptake and coverage can be achieved with opt-in and, even better,
with opt-out policies. There was, however, some evidence of inequit-
able uptake with significantly lower rates of testing amongst older
individuals in half the studies that report this and mixed evidence in
relation to ethnicity and gender.
The quality of the evidence is mixed with only two prospective
controlled studies identified. Many studies were carried out in a
single institution and so generalizability is limited. Other limitations
include a reliance on self-reported data; varying denominators and
exclusions from testing; insufficient details to fully understand inter-
ventions and those with known infection introducing a bias by either
not disclosing status then being tested or refusing testing. Studies
that use serosurvey data usually rely on remnant sera and this
introduces bias as those with sufficient available sera significantly
differ from those without.
General limitations to this review are that only English language
articles were included and only one reviewer carried out the study
selection. Where doubt existed about inclusion, articles were
discussed with the second reviewer and consensus reached. The
second reviewer verified data extraction and bias assessment.
Despite these limitations, the available evidence does support the
feasibility and potential benefits of routine testing (both opt-in and
opt-out) over either risk stratification or on request testing. Non-
routine testing policies only achieve low testing coverage rates and
therefore will miss some individuals with infection.71 However, with
routine HIV opt-in policies, a number of studies also found that a
significant percentage of HIV infection will remain undiag-
nosed.30,38,39,49 Risk-based testing policies rely on knowledge and
acknowledgement of risk; however, studies have shown that those
with newly diagnosed HIV infection frequently do not self-report
traditional risk factors.35,38,72 Further, a risk assessment may be a
barrier to staff offering testing, whilst with routine testing, the test
can be a usual part of the intake routine therefore reducing staff
burden.73,74
Four studies illustrate change in coverage and acceptance with
different testing models. However, all have limitations reducing
the strength of evidence they provide. One study only presents the
crude numbers of tests before and after a change in policy and thus
provides little information about the impact of the change.31
Another compares the implementation of opt-in testing with a
historical period when testing was on request.55 Test acceptance
Figure 2 HIV testing acceptance percentage by type of test offer
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increased from 18 to 73%, but there were so many exclusions from
the opt-in testing offer as to limit the generalizability of these
findings. Two other descriptive studies provide stronger evidence
but are limited by the potential for cohort effects. In Fulton
County Jail, there was an increase from 43% acceptance during
opt-in testing to 64% under opt-out,63 whilst in the Washington
State Department of Corrections, an increase from 5% (testing on
request) to 72% (opt-in) to 90% acceptance (opt-out) was
reported.64
The studies range in place and time from 1989 to 2013 and, as the
epidemiology of HIV infection has changed rapidly in that time,
comparisons are difficult. Interestingly, in the USA, despite the fall
in overall HIV prevalence, increased incarceration has resulted in a
relatively stable number of infections in this population.71
Timing of the testing offer is intrinsically linked with both
meeting eligibility criteria, particularly competence, and being
available for testing. In the USA, the median length of stay in jail
is 2–5 days, 32% of prisoners are under the influence of an illicit
substance upon arrest71 and 29% of detainees are released within
48 h.35 A review of RIDOC HIV testing for 2000-07 showed that 43%
of new HIV infections would have been missed if testing had been
conducted at Day 7.35 Immediate testing has the potential for lower
rates of testing as more individuals are likely to lack capacity to
consent; however, delaying the test allows greater opportunity for
the inmate to have been discharged or moved elsewhere.
HCV prevalence in the prison population is higher than HIV and
therefore new infection identification rates are also higher (ranging
from 12 to 30%). However, evidence relating to routine HBV and
HCV testing is more limited than for HIV. This may be because the
studies identified are predominately from the USA. HBV may be
considered less of an issue in the USA because of routine
immunization of infants. However, HBV prevalence among the
incarcerated is still fivefold that of the general population.75 Few
studies incorporate testing of multiple BBVs and only one study
attempts to link multiple BBV testing with testing acceptance.56
Giving results (both positive and negative) as a part of a routine
testing protocol is feasible. However, considerations need to include
who is going to give the result, confidentiality issues and concerns
about the distress of a diagnosis upon arrival in prison.33 Rapid
testing enables results to be given at the time of testing and
therefore reduces the likelihood of an individual being released
prior to results becoming available; however, confirmatory test
results may still be pending and so for both conventional and
rapid testing regimes, a plan needs to be in place for informing
them of their results post-release. In the USA, those released
within 7-10 days typically do not receive results until after release
which relies on good collaboration with community colleagues.35
Repeat testing is complex with studies describing individuals
having multiple HIV tests.52 At RIDOC in 2000-07, 102 229 tests
were performed on an estimated 40 000–60 000 persons.35 This dem-
onstrates that with opt-out testing, recidivists will likely be tested
multiple times. There is therefore a need for clear policy on repeat
testing: if risk is ongoing, repeat testing at appropriate intervals is
desirable; however, the resource implications need to be considered
for unnecessary repetitive testing.
In the UK, routine opt-out BBV testing has been successful in
other environments. Antenatal HIV opt-out testing has been imple-
mented with a large increase in testing rates, significantly fewer un-
diagnosed cases at delivery and earlier diagnosis.76 In the prison
context, the new BBV policy includes an opt-out test offer for
HIV, HBV and HCV for all prisoners within 72 h of arrival and to
existing prisoners, excluding those tested within the last 12 months
and not subsequently put themselves at risk; known to be positive
for a BBV and for HBV if they have evidence of a negative result and
have been fully vaccinated.20 Further, it includes the concept of a
‘continuous offer’ so that if an individual declines testing, they will
be re-offered at subsequent opportunities.77 This programme has
been implemented in a small number of ‘Pathfinder’ prisons
which will be evaluated prior to national roll-out.78
Conclusion
Although there is little evidence relating to HCV and HBV testing,
routine opt-in and opt-out HIV testing have been shown to be
feasible and acceptable in prisons. Routine opt-out BBV testing
policies should consider a number of issues: (i) The timing of the
testing offer needs to balance three factors: acceptability, competence
and availability. An early testing offer is preferable but with
subsequent testing opportunities for those without capacity on
arrival. (ii) There should be clear exclusion criteria with guidelines
for when an individual reports a recent test (the most common
reason for declining). (iii) Testing methods that do not include
venepuncture should be considered and the population dynamics
support the use of rapid testing when possible. (iv) Clear
protocols are needed for informing individuals of results regardless
of whether they are still in prison or not. (v) Opt-out testing in
prison offers the opportunity to reduce existing disparities in
community BBV testing; however, care needs to be taken to
ensure equitable access to all inmates. (vi) Further research is
needed to explore the ideal time to offer testing in UK prisons
and the perceptions of opt-out BBV testing.
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Key points
 People in prison tend to have both a higher burden of
disease and poorer access to healthcare. Infection with
blood-borne viruses (BBVs) is higher than in the general
population largely due to higher levels of injecting drug use.
 This systematic review found little evidence relating to
hepatitis C virus (HCV) and HBV testing; however,
routine opt-in and opt-out HIV testing have been shown
to be feasible and acceptable in the prison setting.
 A new programme of opt-out BBV testing in England has
recently been implemented in a small number of ‘Pathfinder’
prisons from which lessons will be learned and shared prior
to national roll-out. This literature review will enable
existing evidence on routine BBV testing policies to
inform revisions to the programme.
 Routine opt-out BBV testing policies need to consider a
number of issues: the timing of the testing offer needs to
balance three key factors: acceptability, competence and
availability. Clear exclusion criteria need to be set. Tests
need to be sensitive and specific and the population
dynamic supports the use of rapid testing when possible.
 Good quality control studies of routine testing policies and
further qualitative work around the impact of opt-out
testing in the prison setting are required.
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